8-K current report · filed Nov 9, 2026

TG THERAPEUTICS, INC. (TGTX) 8-K Current Report: November 9, 2026

Item 2.02Item EX-99.1TGTX overview

Short answer

TG THERAPEUTICS, INC. (TGTX) filed an 8-K current report with the SEC on November 9, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Press release covers TG Therapeutics’ third-quarter and nine-month results through September 30, 2026.

TG THERAPEUTICS, INC. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Press release covers TG Therapeutics’ third-quarter and nine-month results through September 30, 2026
  • Exhibit 99.1 contains the financial results and management commentary investors should review
  • Results announcement provides the latest operating update for TGTX, with potential implications for revenue, expenses, cash position and guidance

Item EX-99.1 · Exhibit EX-99.1

  • Q3 revenue $259.9M, up from $161.7M, driven by BRIUMVI U.S. revenue $232.6M, up approximately 52% year over year
  • Full-year 2026 revenue guidance raised to approximately $1B, with BRIUMVI U.S. guidance raised to $915–920M
  • Operating income $85.9M, while net income $55.5M versus $390.9M last year due to the prior-year $365.0M tax benefit
  • Cash, equivalents and investments $556.7M, supporting operations alongside commercial BRIUMVI revenue
  • Approximately $100M repurchased in Q3, 2.0M shares at $49.43 average, signaling capital return and management confidence

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other TG THERAPEUTICS, INC. 8-K filings

Get the next TGTX 8-K as it lands

Follow TGTX for push alerts, or ask the research agent what this filing means.